The World Health Organization (WHO) estimated that in 2019 cancer was the 1st or 2nd leading cause of death under the age of 70 years in 112 of 183 countries. Furthermore, in 2020, more than 19 million new cancer cases were diagnosed and almost 10 million cancer deaths were recorded [1]. Diagnosing cancer in the early stages increases the likelihood of effective treatment and prolongation of the patient's life [2]. Transmembrane glycoprotein - CD44 (P-glycoprotein 1) is a cell surface adhesion receptor, which is highly expressed in many cancers. CD44 also controls metastasis by the expression to the cell surface [3]. Moreover, due to clinicopathological impacts and its isoforms in promoting tumorigenesis CD44 can be considered as a possible molecular target for cancer therapy [4]. The concentrations of cancer biomarkers in the human body in the early stages are quite low. Moreover, matrix effects caused by various species, which are present in body fluids, complicates the detection of biomarkers and normally requires sample dilution prior to testing [5]. Therefore, every opportunity should be taken to increase the sensitivity of immunosensors. One way of doing this is to select antibody that are best suited for immunosensors fabrication. Surface plasmon resonance (SPR) method is traditionally used for evaluation antibody-antigen interaction. Moreover, the calculation of immunoreaction kinetic parameters can be performed by analyzing of SPR results.
The main aim of this work was to investigate the interaction of CD44 protein with specific antibodies. The optimization of interaction conditions was performed. Moreover, the regeneration solution needed for multiple use of SPR sensor was chosen. Few types of specific antibodies against CD44 protein were selected for this work. The kinetics of antibody-antigen interaction were evaluated. Finally, the most suitable for fabrication of immunosensor specific antibodies against CD44 protein was chosen.